Sjögren Syndrome after Radioiodine Therapy in Thyroid Cancer Patients

Salivary and lacrimal gland dysfunction is relatively frequent after radioiodine therapy. In most cases this is a transient side effect, but in some patients it may persist for a long period or appear late. Radioiodine ($^{131}I$) therapy is often administered to patients following total thyroidecto...

Full description

Saved in:
Bibliographic Details
Published inJournal of Oral Medicine and Pain Vol. 43; no. 3; pp. 84 - 86
Main Authors Lee, Hee Jin, Kim, Jae-Jeong, Kim, Young-Gun, Ahn, Hyung-Joon, Choi, Jong-Hoon, Kwon, Jeong-Seung
Format Journal Article
LanguageKorean
Published 2018
Subjects
Thyroid neoplasms
Sj{\ddot{o}}gren^{\prime}s$ syndrome
Xerostomia
Online AccessGet full text

Cover

More Information
Summary:Salivary and lacrimal gland dysfunction is relatively frequent after radioiodine therapy. In most cases this is a transient side effect, but in some patients it may persist for a long period or appear late. Radioiodine ($^{131}I$) therapy is often administered to patients following total thyroidectomy to treat well-differentiated follicular cell-derived thyroid cancer. In addition to the thyroid, $^{131}I$ accumulates in the salivary glands, giving rise to transient or permanent salivary gland damage. Salivary gland dysfunction following radioiodine therapy can be caused by radiation damage. But, it also may be associated with $Sj{\ddot{o}}gren$ syndrome (SS) developed after radioiodine therapy. It would be recommended that the evaluation for SS including anti-SSA/Ro and anti-SSB/La should be considered before and after radioiodine therapy.
Bibliography:KISTI1.1003/JNL.JAKO201831446782619
ISSN:2288-9272